BiotechTube
Home/Pipeline/Vilobelimab

Vilobelimab

Pyoderma Gangrenosum

Phase 3Phase 3 stopped early for futility at interim analysis

Key Facts

Indication
Pyoderma Gangrenosum
Phase
Phase 3
Status
Phase 3 stopped early for futility at interim analysis
Company
InflaRx, InflaRx

About InflaRx

InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.

View full company profile

About InflaRx

InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.

View full company profile

Therapeutic Areas

Inflammation & ImmunologyCritical CareDermatology